Stocktoria
Passage BIO, Inc. PASG
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-02-28
Passage BIO, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D expense | $23.3M | $40.2M | $61.4M | — | — | — | $3.0M |
| Operating income | -$49.3M | -$70.4M | -$108.4M | -$138.4M | -$185.7M | -$112.9M | -$37.2M |
| Income tax | $0 | $0 | — | — | — | — | — |
| Net income | -$45.5M | -$64.8M | -$102.1M | -$136.1M | -$185.4M | -$112.2M | -$45.6M |
| EPS (diluted) | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 | $-2.91 | — |
| Operating cash flow | -$31.5M | -$48.0M | -$78.3M | -$118.2M | -$126.9M | -$80.5M | -$39.9M |
| Cash & equivalents | $46.3M | $37.6M | $21.7M | $34.6M | $129.0M | $135.0M | $158.9M |
| Total assets | $62.3M | $102.4M | $150.5M | $243.5M | $355.1M | $328.0M | $178.6M |
| Total liabilities | $43.5M | $41.2M | $39.3M | $42.2M | $36.4M | $23.3M | $4.3M |
| Shareholders' equity | $18.8M | $61.3M | $111.3M | $201.4M | $318.7M | $304.7M | -$56.3M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.